



# UK Takeover Defence: Summary Guidelines

JULY 2026, PRIVATE AND CONFIDENTIAL

*Akseki & Co*

## Disclaimer

The information contained herein is confidential information supplied on a confidential basis to the recipient for the purpose of providing background information and presenting an opportunity. By accepting this information, the recipient agrees that it will not divulge any such information to any other party. Any reproduction of this information in whole or in part is prohibited. Unless consent is given by Akseki, Sons and Company Limited ("Akseki & Co."), no content of this document, including the proposals made in it, may be copied, reproduced, republished, uploaded, posted, transmitted or distributed in any way.

The information contained herein is for your general information only. Akseki & Co. does not solicit any action based upon such information and it is not and should not be construed as a solicitation or recommendation to acquire or dispose of any investment or to engage in any investment business. Further, you should not rely on any information or opinion contained in this document in making an investment or other decision but should obtain appropriate and specific professional advice.

The information and any opinion contained herein may have been obtained from or are based on sources which are believed to be reliable. Akseki & Co. makes no representation or warranty, express or implied, or assumes any liability or responsibility for, as to the accuracy, reliability or completeness of any information, so obtained and supplied, or any information, estimates, forecasts or opinions prepared on the basis of such information. Opinions, estimates and assumptions constitute our judgment as of the date hereof and are subject to change without notice. Past performance is not indicative of future results.

No information contained in this document constitutes or should be deemed to constitute the provision of financial, investment, tax, legal or other professional advice in any way. Akseki & Co. and any of its affiliates, directors, partners, officers, employees, attorneys, agents and representatives cannot be held responsible for any loss or damage, any loss of profits, loss of business, revenue, data, goodwill or anticipated servicing, whether direct or indirect, resulting from or linked to a decision based on or the use or consultation of this information.

Akseki & Co. is not a regulated institution and does not provide investment advice, financial advice or any other kind of regulated service. Our services are aimed at establishing the best basis for decision makers and executing on their decisions. You are entirely responsible for your use of this document, and for the consequences of relying on any content. Akseki & Co. and any of its affiliates, directors, partners, officers, employees, attorneys, agents and representatives cannot be in any way responsible or assume any liability for any act or omission made by any person in reliance on this document or any information contained herein.

This document has been prepared and issued by Akseki & Co.

# Executive Summary

Takeover defence in the UK is built around disciplined process control, valuation credibility, shareholder engagement and execution-risk pressure.

For an offeree board, the immediate objective is to maintain control of the narrative while complying with the Takeover Code:

- Obtain independent advice,
- Test the bidder's proposal against standalone value and alternatives,
- Consult key shareholders,
- Use the Code timetable to force clarity.

## Core Defence Levers

1. *Valuation Discipline*

2. *Shareholder Mobilisation*

3. *Process Control*

4. *Certainty Pressure*

The board's practical objective is either to move the bidder to a clearly recommendable offer or to create the conditions for a superior outcome, including continued independence, a strategic review or a competing proposal.

# UK Takeover Code Highlights: General Principles

## Equal Treatment

- All holders of the securities of a target company of the same class must be afforded **equivalent treatment**.

## Sufficient Time to Reach Decision

- The holders of the securities of a target company must have **sufficient time and information to enable them to reach a properly informed decision** on the bid; where it advises the holders of securities, the board of the target company must give its views on the effects of implementation of the bid on employment, conditions of employment and the locations of the company's places of business.

## Interests of the Company as a Whole

- **The board of a target company must act in the interests of the company as a whole** and must not deny the holders of securities the opportunity to decide on the merits of the bid.

## No False Markets

- **False markets must not be created** in the securities of the target company, of the bidder or of any other company concerned by the bid in such a way that the rise or fall of the prices of the securities becomes artificial and the normal functioning of the markets is distorted.

## Fully Financed Bids

- **A bidder must announce a bid only after ensuring that it can fulfil in full any cash consideration**, if such is offered, and after taking all reasonable measures to secure the implementation of any other type of consideration.

## Timely Response

- **A target company must not be hindered in the conduct of its affairs** for longer than is reasonable by a bid for its securities.


# Target's Board Reaction: Code Framework

The board's latitude is shaped principally by five features of the Code:

| Rule      | What it does                                                                                            | Board implication                                                                                                                                                                                                                                                                 |
|-----------|---------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rule 21.1 | Restricts actions that could frustrate an offer or deny shareholders the chance to decide on its merits | No poison-pill equivalent: restricted defensive actions generally require shareholder approval or Panel consent. The Panel will normally consent in specified circumstances, including where the offeror consents or the action arises from a qualifying pre-existing obligation. |
| Rule 21.2 | Restricts offer-related arrangements                                                                    | Standard break fees and broader deal protection are usually unavailable, except in narrow cases.                                                                                                                                                                                  |
| Rule 3    | Requires competent independent advice                                                                   | The board must obtain competent independent financial advice; adviser independence, director conflicts and governance arrangements should be addressed at the outset.                                                                                                             |
| Rule 25.2 | Board opinion and recommendation                                                                        | Any public position must be reasoned, defensible and internally consistent with what shareholders are being told.                                                                                                                                                                 |
| Rule 2.6  | Tactical use of timetable                                                                               | Identified bidder must announce firm offer within 28 days or walk away.                                                                                                                                                                                                           |

# Target's Board Reaction: Expected Action Timeline

Following receipt of a credible approach, the target's board will typically organise its response rapidly.



# Target's Board Reaction: UK Takeover Defence Toolkit

Board objective: either move the bidder to a clearly recommendable proposal or create conditions in which a superior outcome emerges.

1

## Valuation narrative

Explain why the proposal undervalues the company and anchor the debate in trading, plan value and strategic options.

Immediate public rejection of low-ball offers: Usually, first move is a firm statement that the proposal materially or fundamentally undervalues the company, coupled with a reasoned standalone case and a “take no action” message.

2

## Register strategy

Engage key holders early, subject to confidentiality, market-abuse and Code disclosure requirements. For a concentrated shareholder register, a relatively small number of institutions may materially influence the outcome.

Mobilisation of key shareholders: For a smaller listed company, the real battleground is usually a short list of institutions. The board will try to understand acceptable price, likely voting behaviour and appetite for independence versus sale.

3

## Deal process

Use PUSU pressure, diligence gating, and — if useful — a formal sale process, private sale process or strategic review.

Running or threatening a competitive process: If a sale may be likely, the board can protect value by broadening the field with formal sale process, private sale process, strategic review or targeted outreach to credible alternatives.

4

## Certainty pressure

Force the bidder to prove financing, regulatory deliverability, timetable realism and management and employee implications.

Making bidders pay for execution risk: Boards can insist on a high-quality package on financing, regulatory path, management retention, pensions, employees and timing before giving access or moving toward recommendation.



## *Akseki & Co.*

### London

The Clubhouse  
8 St James's Square  
London SW1Y 4JU

+44 20 7126 8490

### New York

Suite 1120  
488 Madison Ave.  
New York, NY 10022

+1 212 516 6055

Please direct all written correspondence to our registered address 39 Ellesmere Court,  
Fulham Road London SW10 9TN, United Kingdom.